BRNS BRNS
Company Profile ↓Company Overview
BRNS (BRNS) is a publicly traded company listed on with a market capitalization of $23.28M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.15.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -100.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -100.00% |
Stock Price Performance
| 1 Year: | -55.81% |
| 6 Months: | -23.48% |
| 3 Months: | -12.96% |
| 1 Month: | -9.36% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)42.79 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 64.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 705.00K | 511.00K | 3.25M | 215.00K | 35.00K | 19.00K | 15.02M | 17.06M | 6.17M | 468.00K | 334.00K | 0 | 0 | 0 | 14.97M | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 20.30M | 21.98M | 10.16M | 11.45M | 5.93M |
| Operating Income | -4.65M | -4.34M | -1.43M | -6.17M | -16.84M | -5.54M | 654.00K | 13.23M | 7.24M | -21.48M | -26.34M | -16.11M | -16.91M | -18.29M | -9.38M | -20.30M | -21.98M | -10.16M | -11.45M | -5.93M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -17.63M | -19.14M | -13.73M | -10.24M | -4.68M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 13.00K | 12.00K | 13.00K | 13.00K | 13.00K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -19.68M | -21.15M | -14.64M | -11.16M | -5.55M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -22.00K | -25.00K | -71.00K | -57.00K | -16.00K |
| Net Income | -3.82M | -3.59M | 158.00K | -15.27M | -15.93M | -4.56M | 2.60M | 15.69M | 8.24M | -18.18M | -23.80M | -14.07M | -15.49M | -16.93M | -8.11M | -19.65M | -21.12M | -14.57M | -11.09M | -5.53M |
| Diluted EPS | - | - | 0.01 | -1.90 | -0.64 | -0.13 | 0.07 | 0.41 | 0.22 | -0.48 | -0.62 | -0.37 | -0.40 | -0.43 | -0.21 | -0.49 | -0.52 | -0.36 | - | -0.14 |
| R&D Expense | 4.24M | 3.88M | 3.70M | 4.61M | 4.51M | 4.37M | 10.70M | 9.72M | 9.74M | 9.81M | 13.54M | 15.14M | 11.12M | 11.66M | 11.14M | 8.29M | 7.95M | 5.39M | - | 3.59M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 4.82M | 268.00K | 44.70M | 802.00K | 14.97M | 0 |
| Operating Income | -20.05M | -45.22M | -4.04M | -83.91M | -67.97M | -70.56M |
| Net Income | -17.71M | -50.87M | 5.34M | -73.35M | -61.07M | -66.43M |
| Diluted EPS | -2.24 | -1.96 | 0.14 | -1.91 | -1.55 | -1.64 |
| R&D Expense | 14.39M | 20.37M | 42.35M | 44.87M | 42.24M | 25.56M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 50.67M | - | 270.20M | 214.51M | 160.33M | 98.17M |
| Current Assets | - | - | - | 213.04M | 156.91M | 125.74M | 77.79M |
| Cash & Equivalents | - | 43.27M | - | 194.38M | 142.09M | 110.66M | 70.46M |
| Inventory | - | - | - | - | - | - | - |
| Receivables | - | - | 20.00K | 5.85M | 0 | - | - |
| Total Liabilities | - | 53.81M | - | 27.00M | 27.51M | 30.19M | 23.88M |
| Current Liabilities | - | 7.64M | - | 12.24M | 12.60M | 15.66M | 10.02M |
| Long Term Debt | - | - | - | - | - | - | - |
| Total Debt | - | - | - | 8.77M | 12.98M | 12.01M | 11.28M |
| Total Equity | -22.08M | -36.91M | - | 242.90M | 186.78M | 130.03M | 74.21M |
| Shares Outstanding | - | - | - | 37.68M | 38.64M | 40.23M | 40.85M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -11.03M | -32.58M | -14.43M | -50.92M | -28.94M | -47.98M |
| Investing Cash Flow | -293.00K | -12.91M | -5.75M | -5.41M | -892.00K | 416.00K |
| Financing Cash Flow | 41.44M | 222.74M | 325.00K | 1.87M | 2.16M | 2.00K |
| Capital Expenditure | -293.00K | -1.15M | -6.14M | -5.41M | -892.00K | -37.00K |
| Free Cash Flow | -11.32M | -33.73M | -20.57M | -56.34M | -29.83M | -48.02M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | -415.8% | -16,873.5% | -9.0% | -10,463.1% | -454.1% | - |
| Net Margin % | -367.3% | -18,979.5% | 11.9% | -9,145.5% | -408.0% | - |
| ROE % | 48.0% | - | 2.2% | -39.3% | -47.0% | -89.5% |
| ROCE % | -46.6% | - | -1.6% | -41.6% | -47.0% | -80.0% |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BRNS
12 Health Care Stocks Moving In Monday's Pre-Market Session - Advanced Biomed (NASDAQ:ADVB), Barinthus Bi - Benzinga
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxOc1F5VDlUTWRxMGI1SWNDMndMRDZLMHFpd0Ric0Jvd013aDRzSnc2ZERuWmlwaGc2a2ZFT3ZQclZMTEZPenM0cTFZV2tTLVY3Vm1WcHkyXzhQWGhvTGVTSTM4ejhzYVpKQy1NcVFjNDNvNG1SaVNZNGJrQ25kOU11MFlJTllEYW81X0VsLX…
Barinthus Biotherapeutics PLC (BRNS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTFAtQXlOZkhRWkZLZEhFMEpEN3lwdjBXTXEwVDEzOUViR0k1eXJrZ3B4aVJYX09fbTcwWVl3X2VIa2J6Z0pydGtJRGpVdl9BdzhZQVkxUmZnclI3Y2hlYjZ5VjM4d1FFZF9oeEdRU2VR?oc=5" target="_blank">Barinthus Biotherap…
Are KW, BRNS, AFBI Obtaining Fair Deals for their Shareholders? - Morningstar
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxPTW9vU0MzdU1TSUlaV3VacXBBNHdCc2x6VTVaamtFc2lBenllMTkwSXhqVVhDbEZYRFZEXzBGZnRsYXpLTWcyZWRsbVltZnR3OTc5djhZcWZ6Y2RrcGkzMmoxTi1XTDlKVVhMNnRvb2QzVUpVcnRmTEg3eTlPeDFOLS1qcVpXUXk4YmdTbl…
Barinthus Biotherapeutics (BRNS) Edges Higher: Small Uptick in Low-Priced Stock - Tick Index - po-news-eg.net
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxOdHVOaGUtREF5cWM3VmdfT1dTNXFBRGxDMTlLc3dLQWdteUt5d1NMc29NcmczVDdIUUN0RndYRG04cThLWVYtcFNDVk9HZ1BwcTl0MUJIdE5MVHR3eFlWczZYeXRMTVVOaEt1TTRPdXN4dDhRUFBOT1FpcmM3bkNYQzQ1QU96RGxSLWdzM2…
Barinthus Biotherapeutics To Merge With Privately-Held Clywedog Therapeutics - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxNa3FUNFhuRk1LZERhNjV3Z1U0VERfTGN0LVM0ZXRLR1pYV243NmNzTHQxOXRUSTNySTBIQjB6OWpRY1F5d29YaTM1X1ZmMjBzMU5vOWtNcVpiZV9ENldzYW1VTXlGTWY3ZE9kYXZIS25obC1yVnJYMDNPN0piRjVfdGI2ZVpMNzBxLU9fQm…
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE0yN2lBQUdDNTFxbFB5cDFXM0FyMUJSM1FDMU9mdjdhQXVZbzlrUjhSNlk3U1dNZmJSaFRxX09nLVMwR2hVaXF5U0NHNGk0TU8z?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
BRNS — Frequently Asked Questions
What is the current share price of BRNS?
As of 2026-08-05 17:25 PDT, BRNS trades at $0.57 on NASDAQ/NYSE. Its 52-week range is $0.54 to $1.58.
What is the market capitalisation of BRNS?
BRNS has a market capitalisation of $23.28M on NASDAQ/NYSE.
What is the P/E ratio of BRNS?
BRNS trades at a trailing price-to-earnings (P/E) ratio of -0.35. Its price-to-book (P/B) ratio is 0.31.
What is the return on equity (ROE) of BRNS?
BRNS has a return on equity (ROE) of -89.52%. Its return on capital employed (ROCE) is -80.04%.
Is BRNS a good stock to buy?
This page provides a data-driven analysis of BRNS, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.